Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer

Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer

unknownResults from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more

2017-02-23T10:16:37+00:00October 12th, 2016|Clinical Trials|
This website uses cookies and third party services to provide a better service. Please confirm you are okay with this. I agree